TARSUS PHARMACEUTICALS INC (TARS) Stock Price, Forecast & Analysis
NASDAQ:TARS • US87650L1035
TARS Key Statistics, Chart & Performance
The current stock price of TARS is 75.01 USD. In the past month the price increased by 10.41%. In the past year, price increased by 68.64%.
TARS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TARS. When comparing the yearly performance of all stocks, TARS is one of the better performing stocks in the market, outperforming 85.72% of all stocks.
TARS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TARS. While TARS seems to be doing ok healthwise, there are quite some concerns on its profitability.
TARS Financial Highlights
Over the last trailing twelve months TARS reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 47.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.18% | ||
| ROE | -24.22% | ||
| Debt/Equity | 0.22 |
TARS Forecast & Estimates
16 analysts have analysed TARS and the average price target is 93.2 USD. This implies a price increase of 24.25% is expected in the next year compared to the current price of 75.01.
For the next year, analysts expect an EPS growth of 211.7% and a revenue growth 50.75% for TARS
TARS Ownership
TARS Latest News, Press Relases and Analysis
TARS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.05 | 985.228B | ||
| JNJ | JOHNSON & JOHNSON | 21.14 | 593.362B | ||
| MRK | MERCK & CO. INC. | 22.9 | 307.597B | ||
| PFE | PFIZER INC | 9.04 | 154.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.12 | 125.402B | ||
| ZTS | ZOETIS INC | 18.73 | 56.699B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.207B | ||
| VTRS | VIATRIS INC | 6.35 | 18.503B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.23 | 13.107B | ||
| AXSM | AXSOME THERAPEUTICS INC | 207.52 | 8.567B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TARS
Company Profile
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 323 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Company Info
TARSUS PHARMACEUTICALS INC
15440 Laguna Canyon Road
Irvine CALIFORNIA 92618 US
CEO: Bobak Azamian
Employees: 323
Phone: 19494099820
TARSUS PHARMACEUTICALS INC / TARS FAQ
Can you describe the business of TARSUS PHARMACEUTICALS INC?
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 323 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
What is the current price of TARS stock?
The current stock price of TARS is 75.01 USD. The price increased by 7.79% in the last trading session.
What is the dividend status of TARSUS PHARMACEUTICALS INC?
TARS does not pay a dividend.
How is the ChartMill rating for TARSUS PHARMACEUTICALS INC?
TARS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about TARSUS PHARMACEUTICALS INC (TARS) stock?
16 analysts have analysed TARS and the average price target is 93.2 USD. This implies a price increase of 24.25% is expected in the next year compared to the current price of 75.01.
What is TARSUS PHARMACEUTICALS INC worth?
TARSUS PHARMACEUTICALS INC (TARS) has a market capitalization of 3.18B USD. This makes TARS a Mid Cap stock.
Who owns TARSUS PHARMACEUTICALS INC?
You can find the ownership structure of TARSUS PHARMACEUTICALS INC (TARS) on the Ownership tab.